DISCLAIMER: This product is strictly for research use only. It is meant solely for laboratory testing and in vitro studies-not for use in or on humans or animals. All details provided on this site are for educational purposes. It is illegal to introduce this substance into the body. Only licensed professionals should handle it. This item is not intended to be used as a drug, supplement, or cosmetic, and must not be misrepresented as such.
CJC-1295 (No DAC) + Ipamorelin + Tesamorelin (Blend)
CJC-1295 (no DAC), Ipamorelin, and Tesamorelin are studied together to boost natural growth hormone and IGF-1 levels through complementary pathways that support fat loss, recovery, and hormone balance.
Quantity: 1
All peptides arrive in powdered form for stability
What is CJC-1295 (No DAC) + Ipamorelin + Tesamorelin (Blend)?
CJC-1295 without Drug Affinity Complex (no DAC) is a short-acting analog of growth hormone–releasing hormone (GHRH) that stimulates the pituitary to release growth hormone (GH) in a natural, pulsatile pattern. Ipamorelin is a selective growth hormone secretagogue (GHS) that activates ghrelin receptors to increase GH secretion without significantly affecting cortisol or prolactin. Tesamorelin is a stabilized 44–amino acid GHRH analog that increases GH release and is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy. In research settings, this combination is explored for its potential to enhance GH output, IGF-1 production, and tissue recovery through multiple complementary pathways.
Potential Benefits Shown in Studies
Possible benefits of CJC‑1295 (no DAC) + Ipamorelin + Tesamorelin Blend:
- Maximized GH & IGF‑1 Release
- Accelerated Fat Loss, especially visceral adipose tissue
- Improved Sleep Quality & Mood
- Increased Energy & Cognitive Function
- Enhanced Cellular Repair & Regeneration
- Sustained, Natural GH Production
Mechanisms of Action
CJC-1295 (no DAC) + Ipamorelin + Tesamorelin may work together by:
- CJC-1295 (no DAC): Binding to GHRH receptors to produce short bursts of GH that mimic physiologic release
- Ipamorelin: Activating ghrelin receptors (GHS-R1a) to trigger GH release without large increases in cortisol or prolactin
- Tesamorelin: Stimulating GHRH receptors with a longer-acting profile, increasing GH secretion and promoting fat metabolism
- Increasing circulating IGF-1 to support protein synthesis, collagen formation, and tissue regeneration
- Supporting muscle preservation, fat utilization, and connective tissue health in research models
- Combining short-acting (CJC-1295 no DAC) and longer-acting (Tesamorelin) GHRH analogs for layered GH stimulation
CJC-1295 (No DAC) + Ipamorelin + Tesamorelin (Blend) Research Highlights
Combining GHRH analogs (CJC‑1295, Tesamorelin) with a ghrelin receptor agonist (Ipamorelin) boosts growth hormone and IGF‑1 output via dual pathways.
Source: smithfieldtimes
Tesamorelin is FDA-approved for reducing visceral fat in HIV-associated lipodystrophy, with effects on abdominal adipose tissue confirmed in randomized controlled trials.
Source: jamanetwork
Ipamorelin enhances GH secretion without raising cortisol or prolactin, making it safer than earlier GHRP options.
Source: wikipedia